ID
45412
Description
Principal Investigator: Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA MeSH: https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000548 The study protocol for both cohorts has been previously described (Journal of Thrombosis and Thrombolysis 2012:1-12). HV1 cohort: Briefly 50 healthy volunteers were exposed to two weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by microarray before and after aspirin exposure. The pre-aspirin samples were profiled on the U133A 2.0 array and the post-aspirin samples were profiled on the U1333plus 2.0 array. HV2 cohort: Briefly 53 healthy volunteers were exposed to four weeks of 325mg/day aspirin after which whole blood RNA was collected in PAXgene tubes and profiled by U133plus 2.0 array before and after aspirin exposure.
Link
Keywords
Versions (1)
- 11/20/22 11/20/22 - Chiara Middel
Copyright Holder
Geoffrey Ginsburg, MD, PhD, Institute for Genome Science and Policy, Duke University, Durham, NC, USA
Uploaded on
November 20, 2022
DOI
To request one please log in.
License
Creative Commons BY 4.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
dbGaP phs000548 Aspirin Pharmacogenomics
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
Similar models
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID and consent group of healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, sample ID, and sample use variable obtained from the healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV1] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Subject ID, platelet function score, pre vs. post aspirin time point obtained from healthy participants [HV2] involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
- Sample ID, body site where sample was collected, and analyte type of samples obtained from healthy participants involved in the "Phase I Clinical Trial Describing the Pharmacogenomics of Aspirin" project.
C0680251 (UMLS CUI [1,2])
C1552738 (UMLS CUI [1,2])
C0332152 (UMLS CUI [1,3])